Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer

Trial Details

NCT ID

NCT06361940

Phase

PHASE2

Sponsor

Medical College of Wisconsin

Status

RECRUITING

Cancer Type

ER/PR Positive (Hormone Receptor Positive) Breast Cancer

Interventions

• Aromatase inhibitors or tamoxifen

Locations (sample)

• Milwaukee, Wisconsin, United States|43.0389,-87.90647

Key Eligibility Criteria

• Unilateral diagnostic breast mammogram and ultrasound within 60 days of enrollment.
• Pathologically proven diagnosis of invasive breast cancer, clinical stage I or II.
• Patients must be clinically lymph node negative. Lymph node negativity must be confirmed by clinical exam and/or ultrasound imaging.
• The patient must be female.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.